Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2005 3
2006 1
2007 2
2009 1
2012 2
2014 1
2016 1
2017 1
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Dulaglutide for the treatment of type 2 diabetes.
Scheen AJ. Scheen AJ. Expert Opin Biol Ther. 2017 Apr;17(4):485-496. doi: 10.1080/14712598.2017.1296131. Epub 2017 Feb 28. Expert Opin Biol Ther. 2017. PMID: 28274140 Review.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are injectable agents used for the treatment of hyperglycemia in type 2 diabetes. ...Expert opinion: The once-weekly formulation and the combined positive effects on both glucose control and weight improves patie …
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are injectable agents used for the treatment of hyperglycemia in type 2 diabete …
Albiglutide for the treatment of type 2 diabetes.
Muscogiuri G, Gastaldelli A. Muscogiuri G, et al. Drugs Today (Barc). 2014 Oct;50(10):665-78. doi: 10.1358/dot.2014.50.10.2214156. Drugs Today (Barc). 2014. PMID: 25374965 Review.
The glucagon-like peptide 1 (GLP-1) receptor agonists are a new class of antidiabetic drugs that provide the benefits of decreasing HbA1c and plasma glucose concentrations, stimulating insulin secretion with a very low risk of hypoglycemia, and promoting weight loss …
The glucagon-like peptide 1 (GLP-1) receptor agonists are a new class of antidiabetic drugs that provide the benefits of decreasing H …
Toxic epidermal necrolysis: current evidence, practical management and future directions.
Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE. Chave TA, et al. Br J Dermatol. 2005 Aug;153(2):241-53. doi: 10.1111/j.1365-2133.2005.06721.x. Br J Dermatol. 2005. PMID: 16086734 Review.
We review the literature pertaining to the pathogenesis of TEN and drug reactions in general. The rationale for therapeutic interventions, together with reported evidence of efficacy, are considered. ...Cytotoxicity is mediated by CTL granzyme and possibly death recepto …
We review the literature pertaining to the pathogenesis of TEN and drug reactions in general. The rationale for therapeutic intervent …
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.
Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC; Immune Tolerance Network. Perdigoto AL, et al. Diabetologia. 2019 Apr;62(4):655-664. doi: 10.1007/s00125-018-4786-9. Epub 2018 Dec 19. Diabetologia. 2019. PMID: 30569273 Free PMC article.
The Autoimmunity-Blocking Antibody for Tolerance (AbATE) trial evaluated teplizumab, an Fc receptor non-binding humanised anti-CD3 monoclonal antibody in individuals with new-onset type 1 diabetes, and ended in 2011. ...However, the improvements in C-peptide …
The Autoimmunity-Blocking Antibody for Tolerance (AbATE) trial evaluated teplizumab, an Fc receptor non-binding humanised anti …
Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes.
Shepherd M, Shields B, Hammersley S, Hudson M, McDonald TJ, Colclough K, Oram RA, Knight B, Hyde C, Cox J, Mallam K, Moudiotis C, Smith R, Fraser B, Robertson S, Greene S, Ellard S, Pearson ER, Hattersley AT; UNITED Team. Shepherd M, et al. Diabetes Care. 2016 Nov;39(11):1879-1888. doi: 10.2337/dc16-0645. Epub 2016 Jun 6. Diabetes Care. 2016. PMID: 27271189 Free PMC article.
RESEARCH DESIGN AND METHODS: We studied 808 patients (79.5% of the eligible population) <20 years of age with diabetes who were attending six pediatric clinics in South West England and Tayside, Scotland. Endogenous insulin production was measured using the urinary C-pe …
RESEARCH DESIGN AND METHODS: We studied 808 patients (79.5% of the eligible population) <20 years of age with diabetes who were attending …
IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71).
Bottazzo GF, Bosi E, Cull CA, Bonifacio E, Locatelli M, Zimmet P, Mackay IR, Holman RR. Bottazzo GF, et al. Diabetologia. 2005 Apr;48(4):703-8. doi: 10.1007/s00125-005-1691-9. Epub 2005 Mar 12. Diabetologia. 2005. PMID: 15765222
The clinical requirement for insulin therapy within 6 years was examined in 2,556 patients not randomised to insulin. ...The presence of IA-2A together with GADA increased the relative risk of requiring insulin therapy from 5.4 (4.1-7.1) for GAD …
The clinical requirement for insulin therapy within 6 years was examined in 2,556 patients not randomised to insulin. . …
Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment.
Fagan DH, Uselman RR, Sachdev D, Yee D. Fagan DH, et al. Cancer Res. 2012 Jul 1;72(13):3372-80. doi: 10.1158/0008-5472.CAN-12-0684. Epub 2012 May 9. Cancer Res. 2012. PMID: 22573715 Free PMC article.
The majority of anti-IGF1R clinical trials are in estrogen receptor-positive patients who have progressed on prior endocrine therapy; early reports show no benefit for addition of IGF1R inhibitors to endocrine therapy in this setting. ...We found that …
The majority of anti-IGF1R clinical trials are in estrogen receptor-positive patients who have progressed on prior endocrine …
Effect of the PTPN22 and INS risk genotypes on the progression to clinical type 1 diabetes after the initiation of beta-cell autoimmunity.
Lempainen J, Hermann R, Veijola R, Simell O, Knip M, Ilonen J. Lempainen J, et al. Diabetes. 2012 Apr;61(4):963-6. doi: 10.2337/db11-0386. Epub 2012 Feb 22. Diabetes. 2012. PMID: 22357962 Free PMC article.
We set out to analyze the role of two major non-HLA gene polymorphisms associated with type 1 diabetes (T1D), PTPN22 1858C/T and insulin gene INS-23 A/T in progression to clinical T1D after the appearance of beta-cell autoimmunity. The study population comprised 249 childr …
We set out to analyze the role of two major non-HLA gene polymorphisms associated with type 1 diabetes (T1D), PTPN22 1858C/T and insulin …
Maternal BMI before pregnancy, maternal weight gain during pregnancy, and risk of persistent positivity for multiple diabetes-associated autoantibodies in children with the high-risk HLA genotype: the MIDIA study.
Rasmussen T, Stene LC, Samuelsen SO, Cinek O, Wetlesen T, Torjesen PA, Rønningen KS. Rasmussen T, et al. Diabetes Care. 2009 Oct;32(10):1904-6. doi: 10.2337/dc09-0663. Epub 2009 Jul 10. Diabetes Care. 2009. PMID: 19592628 Free PMC article.
RESEARCH DESIGN AND METHODS: Of 46,939 newborns screened for the high-risk HLA genotype DR4-DQ8/DR3-DQ2, 1,003 were positive and 885 were followed with serial blood samples tested for autoantibodies to insulin, GAD, and insulinoma-associated protein 2 (IA2). The end …
RESEARCH DESIGN AND METHODS: Of 46,939 newborns screened for the high-risk HLA genotype DR4-DQ8/DR3-DQ2, 1,003 were positive and 885 …
Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer.
Köstler WJ, Hudelist G, Rabitsch W, Czerwenka K, Müller R, Singer CF, Zielinski CC. Köstler WJ, et al. J Cancer Res Clin Oncol. 2006 Jan;132(1):9-18. doi: 10.1007/s00432-005-0038-8. Epub 2005 Sep 24. J Cancer Res Clin Oncol. 2006. PMID: 16184380
PURPOSE: Her-2/neu and the insulin-like growth factor-1 receptor (IGF-1R) share common postreceptor-signaling pathways, and pre-clinical models have implicated IGF-1R-signaling in resistance to treatment with the anti-Her-2/neu antibody trastuzumab. ...IGF-1R …
PURPOSE: Her-2/neu and the insulin-like growth factor-1 receptor (IGF-1R) share common postreceptor-signaling pathways, and pr …
14 results